Home / Safety & Regulation / FDA July 2026 peptide review

Breaking

FDA to review 7 peptides for 503A compounding in July 2026: what it actually means

The meeting, in one paragraph

On April 16, 2026, the FDA published a Federal Register notice announcing that its Pharmacy Compounding Advisory Committee will meet on July 23 to 24, 2026 to review seven peptides nominated for inclusion on the Section 503A bulk drug substances list. The committee will consider the substances in both free base and acetate forms. Day one covers BPC-157, KPV, TB-500, and MOTS-c. Day two covers Emideltide (DSIP), Semax, and Epitalon.

The 7 peptides under review

The committee will also review the peptides in both free base and acetate chemical forms, which is standard for compounding review. Five additional peptides are expected to be reviewed by February 2027 in a separate docket that has not yet been fully specified.

What the 503A list actually means, in plain language

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies, the kind that fill individualized prescriptions for a specific patient. The 503A bulk drug substances list is the FDA registry of active ingredients those pharmacies are permitted to use when the ingredient is not already in a USP or NF monograph and is not a component of an FDA-approved drug.

If a raw ingredient is on the list, compounders can legally make prescribed preparations with it. If it is not on the list, they cannot. That is the entire legal question in front of the advisory committee.

The 2023 context, and why these peptides were restricted

In September 2023, the FDA placed a group of peptides into Category 2 of its interim bulk-drug-substances evaluation, the category for substances that may present significant safety risks. That placement functionally barred 503A pharmacies from compounding the listed peptides. STAT reported at the time that the total list included 19 peptides, among them BPC-157, MOTS-c, KPV, Semax, Epitalon, DSIP, and TB-4.

FDA’s published rationale cited immunogenicity concerns, impurity and active ingredient characterization issues, and an absence of human exposure data for most of the substances in question. The Pharmacy Compounding Advisory Committee at the time voted that the substances did not meet the criteria for safe compounding, and the FDA adopted that view.

The July 2026 meeting is, in effect, the agency revisiting those 2023 conclusions.

Why now, and RFK Jr.’s role

HHS Secretary Robert F. Kennedy Jr. has publicly pushed for a revisit of the 2023 peptide restrictions. On the Joe Rogan podcast in late February 2026, Kennedy said, “I’m a big fan of peptides. I’ve used them myself and with really good effect on a couple of injuries.” He also raised a supply-safety concern with the current status quo: “With the gray market you have no idea if you’re getting a good product.” The AP covered the exchange in detail.

Kennedy told Rogan he expected the FDA to “change the status of about 14” peptides within a couple of weeks. That timeline slipped, but the April 16 Federal Register notice is the formal procedural step that puts the question back in front of the advisory committee. Scientific American quoted Kennedy framing the move as restoring “regulated access” and shifting demand “away from the black market.”

What this announcement does not mean

Easy to overread. Here is what it is not.

• Not FDA approval. Inclusion on the 503A list is a compounding pathway, not a statement that the peptide is safe or effective.
• Not a guarantee of a yes vote. The committee can recommend inclusion or exclusion. A vote against is a real possible outcome.
• Not a change in legal status today. The committee is advisory. Any change to the 503A list requires subsequent FDA rulemaking, not just a vote.
• Not a green light for vendors. Gray-market sellers of any of these peptides are still operating outside the regulated pathway.
• Not medical advice. A peptide being reviewed by the committee is not the committee saying it works.

How to submit a public comment

The docket is open at regulations.gov under the docket number FDA-2025-N-6895. Comments submitted on or before July 9, 2026 will be provided to committee members in advance of the meeting. The full docket closes July 22, 2026.

A patient, clinician, or researcher can file a comment. Be specific, cite evidence, be brief.

What I would do right now

Sources

• Federal Register, April 16, 2026. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. Docket FDA-2025-N-6895.
• FDA meeting calendar page, July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting.
• FDA, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Category 2 background, 2023 action.
• Matthew Perrone, FDA to weigh easing limits on unproven peptides favored by RFK Jr., Associated Press via ABC News, April 15, 2026.
• Lizzy Lawrence and Sarah Todd, FDA panel will meet to discuss allowing broader access to certain peptides, STAT News, April 15, 2026.
• Jackie Flynn Mogensen, The Trump administration is looking to experts to weigh in on peptides, Scientific American, April 15, 2026.
• RFK Jr. promotes peptides. Now the FDA weighs easing limits on the unproven chemicals, NBC News, April 15, 2026.
• FDA Considers Adding a Dozen Peptides to Its Bulk Drug Compounding List, Regulatory Affairs Professionals Society (RAPS).

Related reading